Related Experiment Videos
[Therapeutic strategy in advanced breast carcinoma]
M Kaufmann1, G von Minckwitz, S Costa
1Klinik für Gynäkologie und Geburtshilfe, Universitäts-Frauenklinik, Frankfurt am Main.
Praxis
|June 3, 1998
Summary
Metastatic breast cancer to distant sites remains incurable. Treatment decisions for hormone-refractory breast cancer involve careful risk-benefit analysis of chemotherapy, investigational options, or supportive care.
Area of Science:
- Oncology
- Medical Oncology
Context:
- Metastatic breast cancer beyond regional lymph nodes is historically incurable.
- Current treatments include hormonal therapy, surgery, radiation, and chemotherapy for hormone-refractory disease.
Purpose:
- To outline the systemic management strategies for patients with hormone-refractory metastatic breast cancer.
- To describe the decision-making process regarding chemotherapy, investigational therapies, or supportive care.
Summary:
- Systemic management of hormone-refractory breast cancer involves stepwise chemotherapy administration.
- Treatment choices are based on a patient/physician analysis of risks and benefits.
- Options include continuing systemic therapy, exploring investigational agents or high-dose therapy, or opting for supportive care.
Impact:
- Provides a framework for clinical decision-making in advanced breast cancer.
- Highlights the complexities in managing incurable metastatic breast cancer.
- Informs treatment strategies for patients with hormone-refractory disease.